Clinical trials: open to volunteers, in Uganda
Tuberculosis, Latent
Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB
A seamless, staged Phase II/III, open-label, multicenter, non-inferiority trial, to compare the efficacy and safety of 4 weeks of bedaquiline (BDQ) versus a a standard regimen for preventing regimen for preventing confirmed or…
- Trial name
- BREACH-TB (NCT06568484)
- Testing
- Bedaquiline, Isoniazid, rifapentine, Levofloxacin
- Where
- 8 sites in Mongolia, Peru and 2 more
- Volunteers
- 2,530 people
- Sponsor
- Johns Hopkins University
Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)
Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection. The goals of this study are to learn: If taking MK-8527 once a month works to prevent HIV-1 infection better than a…
- Trial name
- NCT07071623
- Testing
- MK-8527, Emtricitabine/tenofovir disoproxil (FTC/TDF)
- Where
- 30 sites in Kenya, South Africa and 1 more
- Volunteers
- 4,580 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Sexually Transmitted Infection (STI), Gonorrhea
A Clinical Study to Assess the Efficacy of Weekly Doxycycline Prophylaxis to Reduce Bacterial Sexually Transmitted Infections (STI) in Young African Women
This study is for people who may get sexually transmitted infections (STIs). Approximately 580 African adolescent and young adult women ages 13-34 in Africa will be included in this study.
- Conditions
- Sexually Transmitted Infection (STI), Gonorrhea, Syphilis, Chlamydia
- Trial name
- NCT07884240
- Testing
- Doxycycline hyclate, Standard of Care for STI prevention
- Where
- 4 sites in Botswana, Eswatini and 2 more
- Volunteers
- 580 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pulmonary Tuberculosis
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
A5409/RAD-TB is an adaptive Phase 2 randomized, controlled, open-label, dose-ranging, platform protocol to evaluate the safety and efficacy of multidrug regimens for the treatment of adults with drug-susceptible pulmonary…
- Trial name
- RAD-TB (NCT06192160)
- Testing
- Isoniazid, Rifampicin, Pyrazinamide
- Where
- 30 sites in Botswana, Brazil and 12 more
- Volunteers
- 315 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection
A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments
The goal of this clinical study is to provide continued access to the study drug(s) to children and adolescents with human immunodeficiency virus type 1 (HIV-1) who completed their participation in an applicable parent study and…
- Trial name
- NCT06337032
- Testing
- F/TAF (High Dose Tablet), F/TAF (Low Dose Tablet), F/TAF (Lowest Dose Tablet)
- Where
- 15 sites in Argentina, Panama and 4 more
- Volunteers
- 350 people
- Sponsor
- Gilead Sciences
Tuberculosis
A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV
This study aims to find the proposed dose of Rifapentine (RPT) taken once daily with Isoniazid (INH) for 28 days to prevent tuberculosis (TB).
- Trial name
- NCT07124559
- Testing
- Rifapentine, Isoniazid, Dolutegravir
- Where
- 11 sites in Botswana, Haiti and 4 more
- Volunteers
- 144 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
Quantitative Measurement and Correlates of the Latent HIV Reservoir in Virally Suppressed Ugandans
Background: Human Immunodeficiency Virus (HIV) is the virus that causes AIDS. HIV can hide in the blood for many years, even in people who have their HIV infection under control.
- Trial name
- NCT02154035
- Where
- Uganda
- Volunteers
- 130 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Metastatic Breast Cancer
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance…
- Trial name
- INAVO122 (NCT05894239)
- Testing
- Inavolisib, Phesgo, Taxane-based Chemotherapy
- Where
- 192 sites in United States, Argentina and 27 more
- Volunteers
- 230 people
- Sponsor
- Hoffmann-La Roche
Tuberculous Meningitis, HIV
BPaLMZ for TB Meningitis
This two-stage study will compare consented research participants with tuberculous meningitis receiving experimental Bedaquiline (B), Pretomanid (Pa), Linezolid (L); Moxifloxacin (M), Pyrazinamide (Z) known as (BPaLMZ) to…
- Conditions
- Tuberculous Meningitis, HIV, Meningitis, TB - Tuberculosis
- Trial name
- BPaLMZ (NCT07227779)
- Testing
- BPaLMZ Regimen
- Where
- 2 sites in Uganda
- Volunteers
- 312 people
- Sponsor
- David Boulware
Rheumatic Heart Disease
Artificial Intelligence to Scale Early Rheumatic Heart Disease Detection
The main goal of this project is to see if RADAR (Rapid AI-assisted Detection and Analysis of Rheumatic heart disease), which is a machine and deep-learning AI model, can help make rheumatic heart disease (RHD) screening easier…
- Trial name
- SHIELD 1 (NCT07599956)
- Testing
- AI assisted echocardiography
- Where
- Uganda
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Tuberculosis, Diagnostics
Rapid Research in Diagnostics Development for TB Network (R2D2 Kids) and Assessing Diagnostics At POC for TB in Children (ADAPT for Kids)
Every year there are an estimated 230,000 childhood deaths from TB. There is an urgent need for novel tests for TB diagnosis in children under 15 years.
- Conditions
- Tuberculosis, Diagnostics, Global Health
- Trial name
- NCT05989802
- Testing
- Oral swab molecular testing, Automated Cough Sound Analysis, Automated Lung Sound Analysis
- Where
- 3 sites in Mozambique, South Africa and 1 more
- Volunteers
- 2,100 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Pulmonary Tuberculosis
Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
The UNITE4TB consortium is a group of universities and pharmaceutical companies funded by the European Union. This consortium are carrying out a trial to find better and faster ways to treat tuberculosis (TB).
- Trial name
- PARADIGM4TB (NCT06114628)
- Testing
- Ganfeborole, BTZ-043, Bedaquiline (B)
- Where
- 11 sites in Moldova, South Africa and 3 more
- Volunteers
- 2,500 people
- Sponsor
- University College, London
Sickle Cell Disease
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
A phase III, multi-center, randomized, placebo-controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult…
- Trial name
- SPARKLE (NCT06439082)
- Testing
- Crizanlizumab
- Where
- 36 sites in United States, Brazil and 3 more
- Volunteers
- 354 people
- Sponsor
- Novartis Pharmaceuticals
Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)
This was Cohort C2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.
- Trial name
- PLATINUM (NCT07811908)
- Testing
- KAE609, SoC (Coartem), KLU156
- Where
- 13 sites in Burkina Faso, Côte d’Ivoire and 5 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Alcohol Misuse, Alcohol Biomarkers
The PEth Results Communication Study
This is a randomized controlled trial (RCT) to test whether adding PEth (a blood test that shows recent alcohol use) to a standard alcohol counseling session in clinic helps people with HIV reduce their drinking.
- Trial name
- PERC (NCT07444359)
- Testing
- PEth-Boosted Brief Intervention
- Where
- Uganda
- Volunteers
- 80 people
- Sponsor
- University of California, San Francisco
Ascariasis
Follow-up Assessment of Change in Soil-transmitted Helminths Infection Intensity in Uganda
The goal of this prospective follow-up study nested within an open-label randomized controlled trial is to investigate the unexpectedly high prevalence of Ascaris lumbricoides infection observed 3-4 months after school-based mass…
- Trial name
- FACEIT-FU (NCT07873398)
- Testing
- Albendazole 400mg, Ivermectin 3 mg
- Where
- Uganda
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Jennifer Keiser
Rheumatic Heart Disease
Testing a Registry-Based Strategy (ACT+) to Reduce Loss to Follow-Up in Rheumatic Heart Disease Screening in Uganda
This study aims to improve follow-up care after positive rheumatic heart disease (RHD) screening in Northern Uganda. It will identify barriers and co-develop an enhanced ACT+ strategy, then evaluate its effectiveness in…
- Trial name
- SHIELD 2 (NCT07606131)
- Testing
- The ACT+ Strategy
- Where
- Uganda
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Well-Being, Psychological, Breastfeeding
Relaxation Intervention to Improve Newborn Growth and Maternal Well-being
The goal of this clinical trial is to learn if listening to a relaxation audiorecording during breastfeeding improves breastfeeding and infant outcomes and maternal well-being in a low-income country setting.
- Conditions
- Well-Being, Psychological, Breastfeeding, Low Birth Weight, Undernutrition
- Trial name
- RING-MW (NCT07774793)
- Testing
- Relaxation audiorecording, Control audio device without relaxation audiorecording
- Where
- Uganda
- Volunteers
- 100 people
- Sponsor
- University of California, San Francisco
Long COVID
Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study
The Long-Covid (LC)-Revitalize clinical study is testing repurposed drug treatments for Long Covid, involving adult participants from Brazil, Canada, Italy, South Africa, Uganda, the United States, and Zambia.
- Trial name
- NCT06928272
- Testing
- Pirfenidone, Upadacitinib
- Where
- 10 sites in United States, Brazil and 5 more
- Volunteers
- 348 people
- Sponsor
- Douglas D. Fraser
HIV/AIDS, HIV/AIDS Prevention
Peer-led Dynamic Choice HIV Prevention for Women: The Peer-led DCP Randomized Trial
This Hybrid Type 1 cluster randomized trial will test the Peer-led Dynamic Choice HIV Prevention (DCP) intervention compared to standard of care.
- Trial name
- NCT07787988
- Testing
- Peer-led Dynamic Choice HIV Prevention (DCP) intervention
- Where
- Uganda
- Volunteers
- 560 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco